1. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of benign prostatic hyperplasia. Urology. 2001; 58(6 Suppl 1): 5 - 16.

2. Пушкарь Д.Ю., Раснер П.И. Симптомы нижних мочевыводящих путей и доброкачественная гиперплазия предстательной железы.//Урология 2006; N 3 (приложение): с. 4 - 18.

3. Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int. 2008; 102: 981 - 6.

4. Management of Non-neurogenic Male LUTS. European Association of Urology Guidelines. http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/

5. Management of Benign Prostatic Hyperplasia. American Urological Association Guidelines. https://www.auanet.org/benign-prostatic-hyperplasia-(2010-reviewed-and-validity-confirmed-2014)

6. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; N 21(2): 167 - 78.

7. Аденома простаты. Урология. Национальное руководство. Ред. Н.А. Лопаткин. М.: Гэотар-Медиа, 2009; с. 852 - 889.

8. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; N 132 (3): 474 - 479.

9. Lytton B., Emery J.M., Harvard B.M. The incidence of benign prostatic hypertrophy. J Urol 1968; N 99 (5): 639 - 645.

10. Сивков А.В. Значение ультразвуковых исследований органов мочеполовой системы при профилактических осмотрах. Диссертация канд. мед. наук., М., 1998, с. 1 - 279.

11. Abrams P, de la Rosette J, Griffiths D, Koyanagi T., Nordling J., Park Y-C., Schafer W., Zimmern P. The diagnosis of bladder outlet obstruction: Urodynamics. In: Cockett AT, Khouri S, Aso Y, Chatelain C., Denis L., Griffiths K., Murphy G. (eds). Proceedings of the 3rd International Consultation on BPH. Paris, SCI, 1995, c. 299 - 356.

12. Torlakovic G., Grover V.K., Torlakovic E. Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume. Croat Med J 2005; N 46 (3): 423 - 428.

13. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., Coyne K., Kelleher C., Hampel C., Artibani W., Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; N 50 (6): 1306 - 14.

14. Chapple C., Abrams P. Lower Urinary Tract Symptoms. In: Male Lower Urinary Tract Symptoms (LUTS). Editors Societe Internationale d'Urologie (SIU). Fukuoka, Japan, 2012. p. 44 - 60.

15. Taoka R., Kakehi Y. The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol 2017; N 4 (3): 158 - 163.

16. Ezz el Din K., Kiemeney L.A., de Wildt M.J., Debruyne F.M., de la Rosette J.J.Correlation between uroflowmetry, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996; N 48 (3): 393 - 397.

17. Barry M.J., Fowler F.J. Jr., O"Leary M.P., Bruskewitz R.C., Cockett AT. The American Urological Association symptom index for benign prostatic hyperplasia. The Committee of the American Urological Association. J Urol 1992; N 148 (5): 549 - 57.

18. D"Silva K.A., Dahm P., Wong C.L. Does this man with lower urinary tract symptoms have bladder outlet obstruction?: The Rational Clinical Examination: a systematic review. JAMA 2014; N 312 (5): 535 - 42.

19. Milsom I., Abrams P., Cardozo L., Roberts R.G., J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; N 87 (9): 760 - 6.

20. Tikkinen K.A., Johnson T.M. Tammela T.L. Sintonen H, Haukka J, Huhtala H, Auvinen A.Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol 2010; N 57 (3): 488 - 496.

21. Van Venrooij G.E., Eckhardt M.D., Gisholf K.W., Boon T.A. Data from frequency-volume charts versus symptom scores and quality of life score in men with lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2001; N 39 (1): 42 - 47.

22. Yap T.L., Cromwell D.C. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int 2007; N 99 (1): 9 - 16.

23. Cornu J.N., Abrams P., Chapple C.R., Dmochowski R.R., Lemack G.E., Michel M.C., Tubaro A., Madersbacher S. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management - a systematic review and meta-analysis. Eur Urol 2012; N 62 (5): 877 - 90.

24. Bosch J.L., Bohnen A.M., Groeneveld F.P. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol 2004; N 46 (6): 573 - 9.

25. Weissfeld J.L., Fagerstrom R.M., O"Brien B.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; N 21 (6 Suppl): 390 - 9.

26. Dong F., Kattan M.W., Steyerberg E.W., Jones J.S., Stephenson A.J., F.H., Klein E.A. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; N 180(1): 150 - 4.

27. Catalona W.J., Partin A.W., Slawin K.M., Brawer M.K., Flanigan R.C., Patel A., Richie J.P., deKernion J.B., Walsh P.C., Scardino P.T., Lange P.H., Subong E.N., Parson R.E., Gasior G.H., Loveland K.G., Southwick P.C. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; N 279 (19): 1542 - 7.

28. Carvalhal G.F., Smith D.S., Mager D.E., Ramos C., Catalona W.J. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less. J Urol 1999; N 161 (3): 835 - 9.

29. Catalona W.J., Richie J.P., Ahmann F.R., Hudson M.A., Scardino P.T., Flanigan R.C., DeKernion J.B., Ratliff T.L., Kavoussi L.R., Dalkin B.L, Waters W.B., MacFarlane M.T., Southwick P.C. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; N 151 (5): 1283 - 90.

30. Bohnen A.M., Groeneveld F.P., Bosch J.L. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol 2007; N 51 (6): 1645 - 52.

31. McConnell J.D., Roehrborn C.G., Bautista O.M., et. al.; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; N 349 (25): 2387 - 98.

32. Lim K.B., Ho H., Foo K.T., Wong M.Y., Fook-Chong S. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol 2006; N 13 (12): 1509 - 13.

33. Abrams P., Chapple C., Khoury S., Roehrborn C., de la Rosette J.; International Consultation on New Developments in Prostate Cancer and Prostate Diseases. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2013; N 189 (1Suppl): S93 - S101.

34. Gerber G.S., Goldfischer E.R., Karrison T.G., Bales G.T. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 1997; N 49 (5): 697 - 702.

35. Rule A.D., Jacobson D.J., Roberts R.O., Girman C.J., McGree M.E., Lieber M.M., Jacobsen S.J. The association between benign prostatic hyperplasia and chronic kidney disease in community-dwelling men. Kidney Int 2005; N 67 (6): 2376 - 82.

36. Lee J.H., Kwon H., Park Y.W., Cho I.C., Min S.K. Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms. Urology 2013; N 82 (6): 1381 - 5.

37. Hong S.K., Lee S.T., Jeong S.J., Byun S.S., Hong Y.K., Park D.S., Hong J.Y., Son J.H., Kim C., Jang S.H., Lee S.E. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int 2010; N 105 (10): 1424 - 8.

38. Oelke M., Kirschner-Hermanns R., Thiruchelvam N., Heesakkers J. Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011. Neurourol Urodyn 2012; N 31 (3): 322 - 6.

39. Mebust W.K., Holtgrewe H.L., Cockett A.T., Peters P.C. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 1989; N 141 (2): 243 - 7.

40. Grossfeld, G.D., Coakley F.V. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am 2000; N 38 (1): 31 - 47.

41. Roehrborn C.G., Bartsch G., Kirby R., Andriole G., Boyle P., de la Rosette J., Perrin P., Ramsey E., Nordling J., De Campos Freire G., Arap S. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001; N 58 (5): 642 - 50.

42. Rule A.D., McGree M.E., Girman C.J., Lieber M.M., Jacobsen S.J. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol 2005; N 174 (Pt 1): 1317 - 21.

43. Sullivan M.P., Yalla S.V. Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol 1996; N 155 (6): 1995 - 2000.

44. Oelke M., K., Jonas U., de la Rosette J.J., Ubbink D.T., Wijkstra H. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol 2007; N 52 (3): 827 - 34.

45. Mochtar C.A., Kiemeney L.A., van Riemsdijk M.M., Laguna M.P., Debruyne F.M., de la Rosette J.J. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol 2006; N 175 (1): 213 - 6.

46. Каприн А.Д., Аполихин О.И., Сивков А.В., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за период 2002 - 2014 гг. по данным официальной статистики. Экспериментальная и клиническая урология 201; N (3): 4 - 16.

47. Jorgensen J.B., Jensen K.M., Mogensen P. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br J Urol 1992; N 69 (3): 265 - 71.

48. Kranse R., van Mastrigt R. Causes for variability in repeated pressure-flow measurements. Urology 2003; N 61 (5): 930 - 4.

49. Idzenga, T., Pel J.J., van Mastrigt R. Accuracy of maximum flow rate for diagnosing bladder outlet obstruction can be estimated from the ICS nomogram. Neurourol Urodyn 2008; N 27 (1): 97 - 8.

50. Reynard J.M., Yang Q., Donovan J.L., Peters T.J., Schafer W., de la Rosette J.J., Dabhoiwala N.F., Osawa D., Lim A.T., Abrams P. The ICS-'BPH' Study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol 1998; N 82 (5): 619 - 23.

51. Oh M.M., Choi H., Park M.G., Kang S.H., Cheon J., Bae J.H., Moon du G., Kim J.J., Lee J.G. Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction? Urology 2011; N 77 (1): 167 - 70.

52. Jeong S.J., Kim H.J., Lee Y.J., Lee J.K., Lee B.K., Choo Y.M., Oh J.J., Lee S.C., Jeong C.W., Yoon C.Y., Hong S.K., Byun S.S., Lee S.E. Prevalence and Clinical Features of Detrusor Underactivity among Elderly with Lower Urinary Tract Symptoms: A Comparison between Men and Women. Korean J Urol 2012; N 53 (5): 342 - 8.

53. Thomas A.W., Cannon A., Bartlett E., Ellis-Jones J., Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004; N 93 (6): 745 - 50.

54. Clement, K., Burden H, Warren K, Lapitan M, Omar M, Drake M. Invasive urodynamic studies for the management of lower urinary tract symptoms (LUTS) in men with voiding dysfunction. Cochrane Database Syst Rev, 2015: CD011179.

55. Stohrer M., Blok B., Castro-Diaz D., Chartier-Kastler E., Del Popolo G., Kramer G., Pannek J., Radziszewski P., Wyndaele J.J. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; N 56 (1): 81 - 8.

56. el Din K.E., Kiemeney LA., de Wildt M.J., Rosier P.F., Debruyne F.M., de la Rosette J.J. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score. J Urol 1996; N 156 (3): 1020 - 5.

57. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009 Nov; 36(4): 403 - 15.

58. Brown, C.T., et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. Bmj, 2007. 334: 25.

59. Dahm P, Brasure M, MacDonald R, Olson CM, Nelson VA, Fink HA, Rwabasonga B, Risk MC, Wilt TJ. Comparative Effectiveness of Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Systematic Review and Meta-analysis.Eur Urol. 2017 Apr; 71(4): 570 - 581.

60. Lepor H. Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol2007; 9: 181 - 90.

61. Woo H.H., Gillman M.P., Gardiner R., Marshall V., Lynch W.J. A practical approach to the management of lower urinary tract symptoms among men. Med J Aust. 2011 Jul 4; 195(1): 34 - 9.

62. Jung JH, Kim J, MacDonald R, Reddy B, Kim MH, Dahm P. Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database Syst Rev 2017; 11: CD012615.

63. Park T, Choi JY. Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis. World J Urol 2014; 32: 1093 - 105.

64. Jae Heon Kim, Min Jung Baek, Hwa Yeon Sun, Bora Lee, Shufeng Li, Yash Khandwala, Francesco Del Giudice, Benjamin I. Chung Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. PLoS One. 2018; 13(10): e0203479.

65. Naslund MJ, Miner M. A review of the clinical efficacy and safety of inhibitors for the enlarged prostate. Clin Ther 2007; 29: 17 - 25.

66. Roehrborn CG. inhibitors prevent the progression of benign prostatic hyperplasia. Rev Urol 2003; 5 Suppl 5: S12 - 21.

67. Roehrborn CG, Siami P, Barkin J, R, Major-Walker K, Nandy I, et al. CombAT Study Group The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123 - 31.

68. Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol 2017; 6: 295 - 304.

69. Favilla V, Russo GI, Privitera S, Castelli T, Giardina R, Calogero AE, et al. Impact of combination therapy 5-alpha reductase inhibitors (5-ARI) plus alpha-blockers (AB) on erectile dysfunction and decrease of libido in patients with LUTS/BPH: a systematic review with meta-analysis. Aging Male 2016; 19: 175 - 81.

70. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving inhibitors: a review and clinical recommendations. J Urol 2006; 176: 868 - 74.

71. Veenboer PW, Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014; 191: 1003 - 8.

72. Gillian Yeowell, 1 Philip Smith, Jameel Nazir, Zalmai Hakimi, Emad Siddiqui, and Francis Fatoye Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018; 8(11): e021889.

73. Sexton CC, Notte SM, Maroulis C, et al. Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 2011; 65: 567 - 85.

74. Chapple, C.R., et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and effi cacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 2013. 63: 296.

75. Herschorn, S., et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the effi cacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology, 2013. 82: 313.

76. Kuo, H.C., et al. Results of a randomized, double-blind, parallel-group, placebo- and activecontrolled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn, 2015. 34: 685

77. Nitti, V.W., et al. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol, 2013. 190: 1320.

78. Wagg A, Nitti VW, Kelleher C, Castro-Diaz D, Siddiqui E, Berner T. Oral pharmacotherapy for overactive bladder in older patients: mirabegron as a potential alternative to antimuscarinics. Curr Med Res Opin. 2016; 32(4): 621 - 38.

79. Giuliano F., et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia//Eur. Urol. - 2013. - Vol. 63. - P. 506 - 616

80. Morelli A., et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats//J. Sex. Med. - 2011. - Vol. 8. - P. 2746 - 2760.

81. Vignozzi L., et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS//Prostate. - 2013. - Vol. 73. - P. 1391 - 1402.

82. Ji Eon Won, Ji Yeon Chu, Hyunah Caroline Choi, Yun Chen, Hyun Jun Park, . Safety and Effectiveness of Once-Daily Tadalafil (5 mg) Therapy in Korean Men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms in a Real-World Clinical Setting: Results from a Post-Marketing Surveillance Study. World J Mens Health. 2018 May; 36(2): 161 - 170.

83. Hyun Jun Park, Ji Eon Joanne Won, Sebastian Sorsaburu, Paul David Rivera, and Seung Wook Lee. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil. World J Mens Health. 2013 Dec; 31(3): 193 - 207.

84. Novara G, Giannarini G, Alcaraz A, JM, Descazeaud A, Montorsi F, Ficarra V. Efficacy and Safety of Hexanic Lipidosterolic Extract of Serenoa repens (Permixon) in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Systematic Review and Meta-analysis of Randomized. Controlled Trials. Eur Urol Focus. 2016 Dec; 2(5): 553 - 561. doi: 10.1016/j.euf.2016.04.002. Epub 2016 Apr 23. Review. PubMed PMID: 28723522.

85. Vela-Navarrete R, Alcaraz A, A, B, JM, Angulo JC, Castro D, Romero-Otero J, Brenes FJ, Carballido J, Molero JM, Ledesma A, Olmos JM, Manasanch Dalmau J, Subirana Cachinero I, Herdman M, Ficarra V. Efficacy and safety of a hexanic extract of Serenoa repens for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018 Dec; 122(6): 1049 - 1065. doi: 10.1111/bju.14362. Epub 2018 Jun 6. PubMed PMID: 29694707.

86. Diaa-Eldin Taha,a,* Omar M. Aboumarzouk,b and Ahmed A. Shokeirc Oral desmopressin in nocturia with benign prostatic hyperplasia: A systematic review of the literature. Arab J Urol. 2018 Dec; 16(4): 404 - 410.

87. Steven A. Kaplan, M.D.,a Jeannette Y. Lee, Ph.D.,b Alan G. Meehan, Ph.D.,c John W. Kusek, Ph.D.,d and Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. Long-term Treatment with Finasteride Resulted in a Significant Improvement Relative to Placebo in Clinical Progression of Benign Prostatic Hyperplasia (BPH) in Men with Enlarged Prostates ( 30 mL), But Not in Those with Smaller Prostates (< 30 mL): Data from the Medical Therapy of Prostatic Symptoms (MTOPS) Trial. *J Urol. 2011 Apr; 185(4): 1369 - 1373.

88. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM, Jr., for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group Combination therapy with doxazosin and finasteride led to a significantly greater reduction in the risk of clinical progression of BPH compared to either drug alone in LUTS patients with a baseline total prostate volume of 25 ml. J Urol. 2006; 175: 217 - 220.

89. Cheuk Fan Shum,* Weida Lau, and Chang Peng Colin Teo Medical therapy for clinical benign prostatic hyperplasia: Antagonists, reductase inhibitors and their combination. Asian J Urol. 2017 Jul; 4(3): 185 - 190.

90. van Kerrebroeck P, Chapple C, Drogendijk T, Klaver M, Sokol R, et al. Combination Therapy with Solifenacin and Tamsulosin Oral Controlled Absorption System in a Single Tablet for Lower Urinary Tract Symptoms in Men: Efficacy and Safety Results from the Randomised Controlled NEPTUNE Trial. Eur Urol. 2013 Dec; 64(6): 1003 - 12.

91. Kim HJ, Sun HY, Choi H, Park JY, Bae JH, Doo SW, et al. Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PLoS One 2017; 12: e0169248.

92. Kaplan, S.A., et al. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract, 2011. 65: 487.

93. Athanasopoulos, A., et al. The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol, 2011. 60: 94.

94. Izard J, Nickel JC. Impact of medical therapy on transurethral resection of the prostate: two decades of change. BJU Int 2011; 108: 89 - 93.

95. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 2009; 36: 403 - 15.

96. Emberton M, Cornel E, Bassi P, Fourcade O, Go'mez M, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 2008; 62: 1076 - 86.

97. NICE. (2010) National Institute for Health and Clinical Excellence. The management of lower urinary tract symptoms in men & Appendices A - H: http://www.nice.org.uk/nicemedia/live/12984/48554/48554.pdf.

98. Ahyai, S.A., et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol, 2010. 58: 384 - 397.

99. Madersbacher S., et al. Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23, 123 cases//Eur. Urol. - 2005. - Vol. 47. - P. 499 - 504. http://www.ncbi. nlm.nih.gov/pubmed/15774249

100. Reich O, Gratzke C, Bachmann A et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol, 2008. 180: 246.

101. Ahyai SA, Lehrich K, Kuntz RM (2007) Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol, 2007. 52: 1456 - 1463

102. Omar, M.I., et al. Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP). BJU Int, 2014. 113: 24.

103. Cornu, J.N., et al. A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update. Eur Urol, 2015. 67: 1066.

104. Mamoulakis, C., et al. Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction. Cochrane Database Syst Rev, 2014. 1

105. Burke, N., et al. Systematic review and meta-analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. Urology, 2010. 75: 1015.

106. Lourenco, T., et al. The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials. World J Urol, 2010. 28: 23.

107. Gratzke, C., et al. Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study. J Urol, 2007. 177: 1419.

108. Varkarakis, I., et al. Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology, 2004. 64: 306.

109. Skolarikos, A., et al. Eighteen-month results of a randomized prospective study comparing transurethral photoselective vaporization with transvesical open enucleation for prostatic adenomas greater than 80 cc. J Endourol, 2008. 22: 2333.

110. Chen, S., et al. Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years. Eur Urol, 2014. 66: 284.

111. Kuntz, R.M., et al. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol, 2008. 53: 160.

112. Li, M., et al. Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. PLoS One, 2015. 10: e0121265.

113. Ou, R., et al. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes > 80 mL: a prospective randomized study. BJU Int, 2013. 112: 239.

114. Rao, J.M., et al. Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia > 80 mL: 12-month follow-up results of a randomized clinical trial. Urology, 2013. 82: 176.

115. Geavlete, B., et al. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison. BJU Int, 2013. 111: 793.

116. Geavlete B., et al. Bipolar vaporization, resection, and enucleation versus open prostatectomy: optimal treatment alternatives in large prostate cases? J Endourol, 2015. 29: 323.

117. Enikeev D, et al. Novel Thulium Fiber Laser for Enucleation of Prostate: A Retrospective Comparison with Open Simple Prostatectomy. J Endourol, 2018 Nov 29. doi: 10.1089

118. Enikeev D, et al. Impact of endoscopic enucleation of the prostate with thulium fiber laser on the erectile function. BMC Urol. 2018 Oct 12; 18(1): 87. Epub 2018 Oct 12

119. Du, C., et al. Holmium laser enucleation of the prostate: the safety, efficacy, and learning experience in China. J Endourol, 2008. 22: 1031.

120. Robert, G., et al. Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP). BJU Int, 2016. 117: 495.

121. Aho, T., et al. Description of a modular mentorship programme for holmium laser enucleation of the prostate. World J Urol, 2015. 33: 497.

122. Chung, D.E., et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol, 2011. 186: 977.

123. Thangasamy, I.A., et al. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012. Eur Urol, 2012. 62: 315.

124. Zhou, Y., et al. Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials. Lasers Med Sci, 2016. 31: 485.

125. Cui, D., et al. A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results. World J Urol, 2014. 32: 683.

126. Yang, Z., et al. Comparison of thulium laser enucleation and plasmakinetic resection of the prostate in a randomized prospective trial with 5-year follow-up. Lasers Med Sci, 2016. 31: 1797.

127. Bouza, C., et al. Systematic review and meta-analysis of Transurethral Needle Ablation in symptomatic Benign Prostatic Hyperplasia. BMC Urol, 2006. 6: 14.

128. Mamoulakis, C., et al. Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting. BJU Int, 2013. 112: 109.

129. Hoffman, R.M., et al. Microwave thermotherapy for benign prostatic hyperplasia. Cochrane Database Syst Rev, 2012. 9: Cd004135.

130. Vanderbrink, B.A., et al. Prostatic stents for the treatment of benign prostatic hyperplasia. Curr Opin Urol, 2007. 17: 1.

131. Malling B, et al. Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. Eur Radiol. 2019 Jan; 29(1): 287 - 298.

132. Kuang M, et al. A Systematic Review of Prostatic Artery Embolization in the Treatment of Symptomatic Benign Prostatic Hyperplasia. Cardiovasc Intervent Radiol. 2017 May; 40(5): 655 - 663.

133. Managing lower urinary tract symptoms in men. https://pathways.nice.org.uk/pathways/lower-urinary-tract-symptoms-in-men#path=view%3A/pathways/lower-urinary-tract-symptoms-in-men/managing-lower-urinary-tract-symptoms-in-men.xml&content=view-index

134. https://www.accessdata.fda.gov/cdrh docs/reviews/DEN160040.pdf

135. Sotelo, R., et al. Robotic simple prostatectomy. J Urol, 2008. 179: 513.

136. Autorino, R., et al. Perioperative Outcomes of Robotic and Laparoscopic Simple Prostatectomy: A European-American Multi-institutional Analysis. Eur Urol, 2015. 68: 86.

137. Pokorny, M., et al. Robot-assisted Simple Prostatectomy for Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement: Surgical Technique and Outcomes in a High-volume Robotic Centre. Eur Urol, 2015. 68: 451.

138. Lucca, I., et al. Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. World J Urol, 2015. 33: 563.

139. Затевахин, И.И., Цициашвили М.Ш., Мишнев А.Д., Трусов О.А. Послеоперационные венозные тромбоэмболические осложнения насколько реальна угроза? Ангиология и сосудистая хирургия. - 2002. - Т. 8. N 1. - С. 17.

140. Donat R, Mancey-Jones B. Incidence of thromboembolism after transurethral resection of the prostate (TURP)--a study on TED stocking prophylaxis and literature review. Scand J Urol Nephrol. 2002; 36(2): 119 - 23.

141. Dyer J, Wyke S, Lynch C. Hospital Episode Statistics data analysis of postoperative venous thromboembolus in patients undergoing urological surgery: a review of 126,891 cases. Ann. R. Coll. Surg. Engl. 2013; 95: 65 - 9.

142. Heiman J., Large T., Krambeck A. Best practice in the management of benign prostatic hyperplasia in the patients requiring anticoagulation. Ther Adv Urol. 2018 Dec; 10(12): 431 - 436.

143. Bejjani BB, Chen DCP, Nolan NG, Edson M. Minidose heparin in transurethral prostatectomy. Urology 1983; 22: 251 - 4.

144. Pushkar D, Vinarov A, Spivak L, Kolontarev K, Putilovskiy M, Andrianova E, Epstein O. Efficacy and safety of Afalaza in men with symptomatic benign prostatic hyperplasia at risk of progression: a multicenter, double-blind, placebo-controlled, randomized clinical trial. Cent European J Urol. 2018; 71(4): 427 - 435. doi: 10.5173/ceju.2018.1803. Epub 2018 Dec 27.

145. Корнеев И.А. "Российский опыт применения суппозиториев Витапрост форте у больных с симптомами нижних мочевых путей и доброкачественной гиперплазией предстательной железы: сравнительный анализ исследований Урология 2017, N 3, стр. 140